MedTrace Logo

Regulation of Bone Formation in Renal Osteodystrophy

NCT00560300 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2010-01-14

No results posted yet for this study

Summary

To examine the effects of two types of active vitamin D (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure

Conditions

  • Secondary Hyperparathyroidism
  • Renal Osteodystrophy

Interventions

DRUG

1 alpha D2

Vitamin D sterol

DRUG

1,25 dihydroxy vitamin D3

Active vitamin D sterol

DRUG

Sevelamer HCl

Phosphate binder

DRUG

Calcium Carbonate

Phosphate binder

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Isidro B Salusky, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Completion
2006-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560300 on ClinicalTrials.gov